Teprotumumab for Thyroid-Associated Ophthalmopathy. - Wikidata - wikimedia - TriplyDB

Teprotumumab for Thyroid-Associated Ophthalmopathy.

Teprotumumab for Thyroid-Associated Ophthalmopathy.

http://www.wikidata.org/entity/Q34556184

about

Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity.Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.Raising awareness of Graves' orbitopathy with early warning cards.Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients.Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?Thyroid disease: Potential new therapy for ophthalmopathy.New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor.CD34- Orbital Fibroblasts From Patients With Thyroid-Associated Ophthalmopathy Modulate TNF-α Expression in CD34+ Fibroblasts and Fibrocytes.Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.

P2860

Q42367245-ABF950A3-1F7A-44F9-9C22-E3280735C047 Q47160950-7BB83A65-BBD2-4303-82AF-02DEBFE07553 Q48325742-6776BB19-850C-4700-BC6C-EEDC14E0D380 Q50254727-24ED69B7-C78C-4E23-BA2D-ADDDB2D8BB75 Q53207209-B6E81D2C-87D4-47F5-AB41-EA6EF7FDE946 Q53282278-B7153CD1-D6B2-46FC-953E-9620D7AAE7BA Q55024151-08074865-573C-4EB7-91C7-6CEAEA247D16 Q55072649-0ACB45E8-706B-4307-AF3B-A83B81A79F3E Q55140443-949EB94B-AF85-4C92-BF47-84883C727506

P2860

Teprotumumab for Thyroid-Associated Ophthalmopathy.

http://www.wikidata.org/entity/Q34556184

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@ast

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@en

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@nl

type

label

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@ast

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@en

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@nl

prefLabel

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@ast

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@en

Teprotumumab for Thyroid-Associated Ophthalmopathy.

@nl

P1433

Q34556184-A045CCA6-59C8-4FCA-98F7-9B5F06679B3B

P1476

Q34556184-89AE2D38-9193-46E1-B571-513072B18D45

P2093

Q34556184-04FB5868-F6F2-4986-A65F-0989248D0EE4

Q34556184-3A4CE8D4-73C0-4F82-A9E0-C520B0D8E991

Q34556184-3D9B0062-52F1-488F-BCEA-E0885D62C141

Q34556184-3DAA7A7F-1BD6-45AB-9E2F-60086FE04E92

Q34556184-525E12C5-3FCE-4F3E-9725-3BF5B6F7A929

Q34556184-67F3E808-7D5E-4A93-9B60-835BB8EF395C

Q34556184-7AF72A26-46D3-41B8-811D-1939312DB883

Q34556184-8376334D-377D-44EC-AB8E-62C81034D2C0

Q34556184-89DEF08F-55A8-4F0C-B1FF-AD225919D28B

Q34556184-A0E247E2-4661-4B88-9123-582E504F2B34

P2860

Q34556184-0BF03901-DD58-4352-8A58-B25D46E38C2D

Q34556184-112B6F35-FDF6-4046-9C7D-1B2CE13734E4

Q34556184-1824E96F-5F81-45F1-8889-E0686B6B797C

Q34556184-1A507461-F2DD-42BF-BEE2-D2E76C51F8F9

Q34556184-1E4EFEE9-4EDE-4AE7-8FF4-28B96424BA2C

Q34556184-2FB06B25-1A59-4370-8D97-EBCD3D522DFB

Q34556184-428C7A8C-6A1E-4A90-A7A8-20B51889A9FE

Q34556184-4AAED71F-8EE1-4BB3-8116-01C9587F5C78

Q34556184-4B30A340-4A47-41FE-9582-C045DF7346D1

Q34556184-56D65F7F-460F-4F40-B12C-102020935C4B

P304

Q34556184-FC2658FC-CEA1-489D-8203-58ABB98C220A

P31

Q34556184-A76D4C75-02E5-4CE2-8E53-4D0D6170321D

P356

Q34556184-C00949FF-B78F-4D04-9F7D-38773EC8169A

P407

Q34556184-F7D3D6A3-45E9-4E63-849C-8E69571A6E2A

P433

Q34556184-1A746E3D-8C70-4167-890F-7DD904FCD821

P478

Q34556184-9EA3DFCB-C890-4C87-835E-ABB9C26E063F

P50

Q34556184-1477F348-01C8-4F00-B6E4-65E8B6728563

Q34556184-2B214558-305E-4422-A2CF-90FAD89E1F73

Q34556184-57C095DB-8525-457A-B995-3F3A961FFB6F

P577

Q34556184-E5CD2D48-5B74-482D-BFBE-BE1EA78DDA33

P698

Q34556184-166F29CB-1E4E-421C-9209-3B3121647D28

P932

Q34556184-D4F515B9-B23E-4C3A-BA00-73F8F79F95E9

P356

P1433

The New England Journal of Medicine

P1476

Teprotumumab for Thyroid-Associated Ophthalmopathy

@en

P2093

Alessandro Antonelli

http://www.w3.org/2001/XMLSchema#string

Brent R Hayek

http://www.w3.org/2001/XMLSchema#string

Daniel G Ezra

http://www.w3.org/2001/XMLSchema#string

Eric M Hink

http://www.w3.org/2001/XMLSchema#string

George J Kahaly

http://www.w3.org/2001/XMLSchema#string

Gerald J Harris

http://www.w3.org/2001/XMLSchema#string

Guido Magni

http://www.w3.org/2001/XMLSchema#string

James C Fleming

http://www.w3.org/2001/XMLSchema#string

James W Gigantelli

http://www.w3.org/2001/XMLSchema#string

Kathleen Gabriel

http://www.w3.org/2001/XMLSchema#string

P2860

The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy

Graves' Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies.

Graves' Disease.

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

Increased generation of fibrocytes in thyroid-associated ophthalmopathy.

Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.

Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Randomized controlled trial of rituximab in patients with Graves' orbitopathy

Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL.

P304

1748-1761

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1614949

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

376

http://www.w3.org/2001/XMLSchema#string

P50

Raymond S Douglas

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28467880

http://www.w3.org/2001/XMLSchema#string

P932

5718164

http://www.w3.org/2001/XMLSchema#string